'Median pfs' diaporamas de présentation

1.11k views • 87 slides

Forging a new standard in metastatic CRC

Forging a new standard in metastatic CRC. Eric Van Cutsem University Hospital Gasthuisberg Leuven, Belgium. Advances in the treatment of mCRC. 1980 1985 1990 1995 2000 2005 2010. Best supportive care. 5-FU.

560 views • 44 slides

887 views • 40 slides

Targeting ALK in Advanced NSCLC A New Treatment Paradigm

Targeting ALK in Advanced NSCLC A New Treatment Paradigm. Alice T. Shaw, MD PhD Massachusetts General Hospital Cancer Center Harvard Medical School August 25, 2012. Oncogenic Drivers in NSCLC. KRAS 24% 1. EGFR 13% 1. PIK3CA 4% 1. RET ~1% 5. ALK 3% 2. M ET ~1% 4. HER2 2 % 3.

1.23k views • 32 slides

Novel Agents for Indolent L ymphoma and Mantle Cell Lymphoma

Novel Agents for Indolent L ymphoma and Mantle Cell Lymphoma. Stephen Ansell, MD, PhD Mayo Clinic. Would we expect mantle cell lymphoma and follicular lymphoma to respond to similar agents?. Tiacci et al, Nature Reviews Cancer 6, 437- 448, 2006.

452 views • 24 slides